中国兽药杂志2026，Vol.60Issue(7)：49-59,11.DOI:10.11751/ISSN.1002-1280.2026.7.07
上海宠物源产ESBLs肺炎克雷伯菌分子特征研究
Study on the Molecular Characterization of Extended-Spectrum Beta-Lactamases-Producing Klebsiella pneumoniae of Pets in Shanghai
摘要
Abstract
To investigate the resistance phenotypes and molecular characteristics of pet-derived extended-spectrum beta-lactamases(ESBLs)-producing Klebsiella pneumoniae in Shanghai,51 K.pneumoniae isolates from dogs and cats were studied.The micro broth dilution method was used to determine the ESBLs phenotype and the antimicrobial susceptibility of ESBLs-producing K.pneumoniae.Selected strains for whole-genome sequencing to analyse antibiotic resistance genes,virulence factors,ST types,and phylogenetic relationships.The results showed that the isolation rate of ESBLs-producing K.pneumoniae was 35.3%,and these strains were predominantly multidrug resistance(94.4%).The highest resistance rates were observed against Ampicillin(100%),followed by Gentamicin and Ceftiofur(both 94.4%),while the resistance rate to Colistin was the lowest(11.1%).The strains extensively harboured SHV-type β-lactamase resistance genes(100%)and CTX-M-15 genes(40.0%),among others.The virulence factors primarily identified were fimbriae and siderophores,and three high-virulence biomarker genes were detected.ST15 and ST307 were identified as the most prevalent clonal lineages(each accounting for 20%of isolates)and were found to harbour the CTX-M-15,OXA-1,and SHV-28 gene combinations.This study indicates that the antimicrobial resistance situation among ESBLs-producing K.pneumoniae isolated from pets in Shanghai is severe.There is an urgent need to strengthen oversight of veterinary drug use and incorporate pet-derived K.pneumoniae into antimicrobial resistance surveillance systems.关键词
超广谱β-内酰胺酶/宠物/肺炎克雷伯菌/全基因组测序Key words
extended-spectrum beta-lactamase/pet/Klebsiella pneumoniae/whole-genome sequencing分类
农业科技引用本文复制引用
蔡昱婷,姜芹,张妤,孙冰清,方雅红,张亦菲,程敏..上海宠物源产ESBLs肺炎克雷伯菌分子特征研究[J].中国兽药杂志,2026,60(7):49-59,11.基金项目
农业农村部动物源细菌耐药性监测重点实验室开放课题(NYX2024002) （NYX2024002）
